Amarin Corp Plc - Company Profile
Powered by 
All the sales intelligence you need on Amarin Corp Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Amarin Corp Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Amarin Corp Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Amarin Corp Plc (Amarin) is a pharmaceutical company focused on the development and commercialization of therapeutics aimed at improving cardiovascular health and reducing cardiovascular risk. The company is in the development and commercialization of VASCEPA (icosapent ethyl), which is marketed under the brand name VAZKEPA in Europe.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Amarin has a robust research and development program focused on advancing cardiovascular health through its flagship product, VASCEPA (icosapent ethyl). The company's R&D initiatives are centered around exploring new therapeutic indications and enhancing existing ones, primarily through clinical trials and strategic collaborations. A key component of these efforts is the REDUCE-IT cardiovascular outcomes study, which has demonstrated a significant reduction in cardiovascular risk beyond cholesterol-lowering therapy in high-risk patients. Amarin has also entered into strategic collaborations, such as with Mochida Pharmaceutical Co Ltd to develop new products and indications based on eicosapentaenoic acid (EPA). Additionally, the company conducts various clinical trials to expand the therapeutic applications of VASCEPA and is actively pursuing regulatory approvals across multiple jurisdictions. In FY2025, the company spent US$19.8 million on its R&D activities, which as a percentage of revenue stood at 9.3%.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer